Organization | Simbec-Orion

Simbec-Orion Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Merthyr Tydfil United Kingdom (1974)

Status: Defunct (2019)

Organization Overview

First Clinical Trial

2000

NCT00004219

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Drugs in Phase 4 Trials (1)

fluoroestradiol (1 trial)

Drugs in Phase 3 Trials (8)

Key: Simbec-Orion (3) Acquired (5)

gemcitabine (gemzar) (1 trial)

granisetron (kytril) (1 trial)

gv 1001 (1 trial)

lerisetron (1 trial)

methoxyflurane (penthrane) (1 trial)

multivirus (cmv, ebv, adv)-specific t cells (1 trial)

propofol (diprivan) (1 trial)

remimazolam (1 trial)

Drugs in Phase 2 Trials (5)

Key: Simbec-Orion (2) Acquired (3)

aldesleukin (proleukin) (1 trial)

cytisine (3 trials)

imatinib (gleevec) (1 trial)

trovafloxacin (trovan) (1 trial)

trovax (1 trial)

Drugs in Phase 1 Trials (48)

Key: Simbec-Orion (44) Acquired (4)

acetaminophen (tylenol) (1 trial)

adc-3680 (1 trial)

aluminum hydroxide (Gaviscon) (1 trial)

atx2417 (1 trial)

ax-024 (2 trials)

aztreonam (azactam) (1 trial)

bn201 (1 trial)

budesonide (rhinocort) (2 trials)

ceftazidime (fortaz) (1 trial)

clonidine (catapres) (1 trial)

Dexketoprofen (1 trial)

diclofenac (voltaren) (1 trial)

estradiol (progynon depot) (1 trial)

f901318 (3 trials)

fdl169 (2 trials)

formoterol (foradil) (2 trials)

gbs-nn/nn2 (1 trial)

glyceryl trinitrate (1 trial)

glycopyrronium (robinul) (2 trials)

gmc-252-l-lysine (2 trials)

hrbmp4 (1 trial)

hydrocortisone (solu-cortef) (3 trials)

hydroxycarbamide (1 trial)

ibuprofen (motrin) (6 trials)

itraconazole (sporanox) (1 trial)

m01zh09 (1 trial)

metoprolol (lopressor) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

nitrous oxide (1 trial)

oc-000459 (2 trials)

oligog cf-5/20 (1 trial)

piperacillin (pipracil) (1 trial)

pnubiovax (1 trial)

pseudoephedrine (Benylin) (1 trial)

rdc5 (1 trial)

tazobactam (Zosyn) (1 trial)

test (1 trial)

testosterone (delatestryl) (1 trial)

tiotropium (spiriva) (1 trial)

tromethamine (tham) (1 trial)

ue2343 (1 trial)

urea (5 trials)

zh9pa (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Pain (Phase 1)

Adrenal Hyperplasia, Congenital (Phase 1)

Adrenal Insufficiency (Phase 1)

Adrenogenital Syndrome (Phase 1)

Aspergillosis (Phase 1)

Cystic Fibrosis (Phase 1)

Demyelinating Diseases (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Ear Diseases (Phase 1)

Erectile Dysfunction (Phase 1)

Fever (Phase 1)

Fibrosis (Phase 1)

Hepatic Insufficiency (Phase 1)

Hyperplasia (Phase 1)

Hypersensitivity (Phase 1)

Hypogonadism (Phase 1)

Labyrinth Diseases (Phase 1)

Labyrinthitis (Phase 1)

Liver Failure (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Nausea (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Neuritis (Phase 1)

Optic Neuritis (Phase 1)

Pneumococcal Infections (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Seminoma (Phase 3)

Streptococcal Infections (Phase 1)

Typhoid Fever (Phase 1)

Vomiting (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 65
# of Trial APIs: 62